News

City of San Antonio enacting plan to better leverage military medical assets

  The San Antonio Military Life Science Commercialization Action Plan seeks to better leverage ...

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Featured image is of SwRI staff working in their cGMP clean room where clinical supplies of their ...

Events

Learn to Prepare IND for Small Molecule Drugs

How does a drug development program evolve from a brilliant research idea? Join Southwest Research Institute ...
News
Biotech firm completes study on skin wart treatment
February 20, 2014

By Mike W. Thomas, San Antonio Business Journal

Local biotech firm ViroXis Corp. is wrapping up a Phase 2 clinical study of its treatment for a virus that causes skin warts.

The final patient of the 183-person enrolled study has completed treatment and the results will be known once the data has been analyzed. ViroXis has developed a drug for treating the Human Papilloma Virus (HPV) using oils from the East Indian Sandalwood tree. The study is being funded by the proceeds of a $5 million Series B private offering.

ViroXis also announced plans to initiate a second Phase 2 clinical study in a new direction to test its effect on Molluscum contagiosum (MCV) in a pediatric population. MCV is a highly contagious pox virus skin infection for which there are currently no approved prescription treatments.

"ViroXis has quickly emerged as leader in the development of botanical drug products, a new and important group of drug candidates afforded a distinct approval process by the (Food and Drug Administration)," says Ian Clements, CEO of ViroXis.

 

Stay informed. Subscribe to BioMed SA news alerts.